Search Results

You are looking at 1 - 10 of 2,588 items for :

  • Refine by Access: All x
Clear All
Full access

Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

patient advocacy, community oncology, and health information technology representatives, to review the existing quality landscape and identify contemporary, relevant cancer quality and outcomes measures by both reevaluating current validated measures and

Full access

Neoadjuvant Chemotherapy in Stage III NSCLC

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

trial and update of systematic review . Lancet 2007 ; 369 : 1929 – 1937 . 27. Dautzenberg B Benichou J Allard P . Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results

Full access

Management of Metastatic Renal Cancer

Patricia Thompson and Mayer Fishman

. Immunotherapy of metastatic renal cell cancer . Review . Cancer Control 2002 ; 9 : 293 – 304 . 3 Motzer RJ Bander NH Nanus DM . Renal-cell carcinoma . N Engl J Med 1996 ; 335 : 865 – 875 . 4 Motzer RJ Mazumdar M Bacik J . Survival

Full access

New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations

Saroj Niraula and Zoann Nugent

reviewed by an independent national process called the pan-Canadian Oncology Drug Review (pCODR), a branch of Canadian Agency for Drugs and Technologies in Health (CADTH). With the stated objective “to bring consistency and clarity to the assessment of

Full access

Oncology Drug Review Process

Ann T. Farrell and Richard Pazdur

Drug Development Programs: Designation, Development, and Application Review. Washington, DC , United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics

Full access

PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, and May T. Cho

and effectively treated with an ICI. We also review the literature on immunotherapy use in patients with other metastatic solid tumors after liver transplant and those with baseline liver function abnormalities. Case Presentation A 61-year-old man with

Full access

Pathology of Soft Tissue Sarcoma

Brian P. Rubin and John R. Goldblum

. Grading of soft tissue sarcomas. Review and update . Arch Pathol Lab Med 2006 ; 130 : 1448 – 1453 . 26. Hasegawa T Yamamoto S Yokoyama R . Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft

Full access

Maintenance Chemotherapy in Non–Small Cell Lung Cancer

Keith D. Eaton and Renato G. Martins

participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscapecme.com/journal/jnccn ; (4) view

Full access

Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review

Andrew S. Epstein and Eileen M. O'Reilly

of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www

Full access

CLO19-042: Quality Assurance for Cancer Radiotherapy: An Update on the Ottawa Hospital Peer Review Experience

Shawn Malone, Eduardo Gaviolli, Julia Malone, and Julie Renaud

Background: Peer review is an important quality assurance (QA) tool in cancer care. For radiotherapy (XRT), peer review is challenging because of the complexity of XRT targets and treatment planning and significant patient numbers. During review